Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III TrialDaniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
The New England Journal of Medicine|January 10, 2024
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
The New England Journal of Medicine|February 5, 2025
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive CancerAlison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Nature Cancer|June 17, 2022
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapyThomas Walle, Sunanjay Bajaj, Joscha A Kraske, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2022
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trialPaula Ghaneh, Daniel Palmer, Silvia Cicconi, et al.
Cancer Discovery|May 27, 2018
NRG1 Fusions in KRAS Wild-Type Pancreatic CancerChristoph Heining, Peter Horak, Sebastian Uhrig, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Clinical practice and implications of biomarker testing in biliary tract cancer: An observational studySabrina Welland, Ann-Kristin Zöller, Ilektra A Mavroeidi, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Hierarchical classification of immune cell transcriptomes at population-scaleChristopher Beltz, Zekai Qiu, Leon Sadowski, et al.
Hepatology (Baltimore, Md.)|November 2, 2023
Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCCAnna-Lena Scherr, Luisa Nader, Kaiyu Xu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 19, 2022
Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinomaPaula Hoffmeister-Wittmann, Andreas Mock, Federico Nichetti, et al.
Pageof 13